32 results
8-K
EX-10.1
CNSP
Cns Pharmaceuticals Inc
2 Feb 24
Entry into a Material Definitive Agreement
5:00pm
to result in a Material Adverse Effect. None of the Company’s or its Subsidiaries’ employees is a member of a union that relates to such employee’s
424B4
CNSP
Cns Pharmaceuticals Inc
31 Jan 24
Prospectus supplement with pricing info
4:27pm
to the WPD Sublicense. The grant will be co-funded by the European Union, under the Smart Growth Operational Program 2014-2020, Sectoral Programme … licensing, pricing and reimbursement vary greatly from country to country.
Under European Union regulatory systems, marketing authorizations may
8-K
EX-10.2
tuyxg877
1 Dec 22
CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price
5:19pm
8-K
EX-10.1
s8k666rfknyui1r
1 Dec 22
CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price
5:19pm
8-K
EX-10.1
xalhokcnhi2q5j3l6ps
6 Jan 22
CNS Pharmaceuticals Announces $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
9:11am
8-K
EX-1.1
um1ey
12 Feb 21
Entry into a Material Definitive Agreement
5:13pm
S-3
EX-4.1
it0wbr
27 Jan 21
Shelf registration
4:02pm
S-3
EX-4.2
3nn6mwnfx
27 Jan 21
Shelf registration
4:02pm